One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD

BACKGROUND: Arformoterol tartrate (arformoterol, 15 μg bid) is a nebulized long-acting β(2)-agonist approved for maintenance treatment of COPD. METHODS: This was a multicenter, double-blind, randomized, placebo-controlled study. Patients (aged ≥ 40 years with baseline FEV(1) ≤ 65% predicted, FEV(1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Donohue, James F., Hanania, Nicola A., Make, Barry, Miles, Matthew C., Mahler, Donald A., Curry, Lisa, Tosiello, Robert, Wheeler, Alistair, Tashkin, Donald P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Chest Physicians 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251615/
https://www.ncbi.nlm.nih.gov/pubmed/25451347
http://dx.doi.org/10.1378/chest.14-0117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251615/
https://www.ncbi.nlm.nih.gov/pubmed/25451347
http://dx.doi.org/10.1378/chest.14-0117

Ejemplares similares